Literature DB >> 26432439

Inhibition of osteoclastogenesis through siRNA delivery with tunable mesoporous bioactive nanocarriers.

Tae-Hyun Kim1, Rajendra K Singh1, Min Sil Kang1, Joong-Huyn Kim1, Hae-Won Kim2.   

Abstract

Gene silencing through siRNA delivery has shown great promise for treating diseases and repairing damaged tissues, including bone. This report is the first to develop siRNA delivery system in the inhibition of osteoclastic functions which in turn can help turn-over bone mass increase in the diseases like osteoporosis. For this reason, biocompatible and degradable nanocarriers that can effectively load and deliver genetic molecules to target cells and tissues are being actively sought by researchers. In this study, mesoporous bioactive glass nanospheres (MBG), a novel unique biocompatible degradable inorganic nanocarrier, is introduced. Furthermore, siRNA was designed to function by inhibiting the expression of the receptor activator of nuclear factor kappa B (RANK) in order to suppress osteoclastogenesis. Amine-functionalized MBG were synthesized with tunable mesoporosities, showing a strong complexation with siRNA. An in vitro release profile indicated that the siRNA from the MBG was able to achieve a highly sustainable liberation for up to 4 days, confirming a temporary delivery system can be designed to function for that period of time. The intracellular uptake capacity of the complex siRNA(RANK)-MBG was recorded to be around 70%. Furthermore, the RANK-expressing cell population declined down to 29% due to the delivery of siRNA(RANK)-MBG (vs. 86% in control). The expression of osteoclastogenesis-related genes, including c-fos, cathepsin-K, tartrate-resistant acid phosphatase (TRAP), and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), was substantially down-regulated by the siRNA delivery system. This study reports for the first time on the use of a novel MBG delivery system for siRNA that aims to suppress osteoclastic actions. MBGs may be a potential gene delivery platform for hard tissue repair and disease treatment due to the collective results which indicate a high loading capacity, temporary release kinetics, high intracellular uptake rate, and sufficient gene silencing effects, together with the intrinsic beneficial properties like bone-bioactivity and degradability. STATEMENT OF SIGNIFICANCE: This report is the first to develop siRNA delivery system of biocompatible and degradable nanocarriers made from a unique composition, i.e., mesoporous bioactive glass that can effectively load and deliver genetic molecules to osteoclastic cells. We proved through a series of studies that the biocompatible nanocarriers are effective for the delivery of siRNA in the inhibition of osteoclastic functions which thus might be considered as a nanocarrier platform to help turn-over bone mass increase in the diseases like osteoporosis.
Copyright © 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mesoporous bioactive glass; Nanocarriers; Osteoclast inhibition; RANK; siRNA delivery

Mesh:

Substances:

Year:  2015        PMID: 26432439     DOI: 10.1016/j.actbio.2015.09.035

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  11 in total

1.  [Osteogenic effect of collagen/bioglass composites carrying noggin siRNA].

Authors:  Yanling Chen; Liangjiao Chen; Zhengmao Li; Zedong Lan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

Review 2.  Use of nanoparticles in skeletal tissue regeneration and engineering.

Authors:  Miriam Filippi; Gordian Born; Delphine Felder-Flesch; Arnaud Scherberich
Journal:  Histol Histopathol       Date:  2019-11-13       Impact factor: 2.303

Review 3.  Development of nanomaterials for bone-targeted drug delivery.

Authors:  Hao Cheng; Aditya Chawla; Yafeng Yang; Yuxiao Li; Jin Zhang; Hae Lin Jang; Ali Khademhosseini
Journal:  Drug Discov Today       Date:  2017-05-06       Impact factor: 7.851

Review 4.  Recent advances and future perspectives of sol-gel derived porous bioactive glasses: a review.

Authors:  Kalim Deshmukh; Tomáš Kovářík; Tomáš Křenek; Denitsa Docheva; Theresia Stich; Josef Pola
Journal:  RSC Adv       Date:  2020-09-11       Impact factor: 4.036

5.  Mesoporous Silica-Based Nanoparticles as Non-Viral Gene Delivery Platform for Treating Retinitis Pigmentosa.

Authors:  Lourdes Valdés-Sánchez; Sara Borrego-González; Adoración Montero-Sánchez; Simone Massalini; Berta de la Cerda; Aránzazu Díaz-Cuenca; Francisco J Díaz-Corrales
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

6.  Nanoparticles to Knockdown Osteoporosis-Related Gene and Promote Osteogenic Marker Expression for Osteoporosis Treatment.

Authors:  Patricia Mora-Raimundo; Daniel Lozano; Miguel Manzano; María Vallet-Regí
Journal:  ACS Nano       Date:  2019-05-13       Impact factor: 15.881

Review 7.  The Delivery of RNA-Interference Therapies Based on Engineered Hydrogels for Bone Tissue Regeneration.

Authors:  Tingting Yu; Hufei Wang; Yunfan Zhang; Xing Wang; Bing Han
Journal:  Front Bioeng Biotechnol       Date:  2020-05-12

Review 8.  Mesoporous Bioactive Glasses Cytocompatibility Assessment: A Review of In Vitro Studies.

Authors:  Margaux Salètes; Marta Vartin; Caroline Mocquot; Charlène Chevalier; Brigitte Grosgogeat; Pierre Colon; Nina Attik
Journal:  Biomimetics (Basel)       Date:  2021-01-23

9.  Improvement of Biological Effects of Root-Filling Materials for Primary Teeth by Incorporating Sodium Iodide.

Authors:  Ji-Myung Choi; Huong Thu Vu; Seong-Jin Shin; Jun-Yong Ahn; You-Jin Kim; Sol Song; Mi-Ran Han; Jun-Haeng Lee; Jong-Soo Kim; Jonathan C Knowles; Hae-Hyoung Lee; Ji-Sun Shin; Jong-Bin Kim; Jung-Hwan Lee
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.411

Review 10.  Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis.

Authors:  Miguel Gisbert-Garzarán; Miguel Manzano; María Vallet-Regí
Journal:  Pharmaceutics       Date:  2020-01-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.